SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 08, 2011 08:16 ET

Neoprobe and Medivation Hope to Navigate FDA's Tougher Safety Stance

The Paragon Report Provides Equity Research on Neoprobe & Medivation

NEW YORK, NY--(Marketwire - Nov 8, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly disappointing earnings elicit large movements in stock prices. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Neoprobe Corporation (NASDAQ: NEOP) and Medivation, Inc. (NASDAQ: MDVN). Access to the full company reports can be found at:

Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

This earnings season has been cruel to the biotech industry. Dendreon's announcement that sales of its revolutionary prostate cancer drug, Provenge, have come in significantly below expectations for the year has caused a downward push for the entire sector, as investors abandon shares of firms nearing the launch of other highly anticipated drugs.

Dendreon's news directly benefitted Medivation, Inc. Last week the company announced that its experimental treatment for advanced prostate cancer helped men live longer (a 37% reduction in risk of death compared with a placebo). Median overall survival rate for men taking Medivation's drug was almost five months longer than those treated with a placebo.

Neoprobe's loss from operations for the third quarter of 2011 was $6.5 million compared to $3.6 million for the third quarter of 2010.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at